Correlation of PET-CT Studies With Serum Protein Analysis

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00547742
First received: October 19, 2007
Last updated: July 16, 2010
Last verified: July 2010
  Purpose

To correlate serum proteomics patterns with PET/CT findings to improve cancer diagnosis, staging, prognosis, and therapy monitoring.


Condition Intervention
Carcinomas (Including Squamous Cell and Adenocarcinoma)
Procedure: PET/CT Scan
Procedure: phlebotomy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Correlation of PET-CT Studies With Serum Protein Analysis

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples Without DNA

blood


Estimated Enrollment: 1500
Study Start Date: July 2005
Study Completion Date: June 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients having PET/CT scans

Criteria

Inclusion Criteria:1. Patients must have a PET/CT study performed at the time of blood collection.

2. Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them.

Exclusion Criteria:1. Patients who are not eligible for a PET/CT study.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00547742

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Dr Andrew Quon Stanford University
  More Information

No publications provided

Responsible Party: Dr Andrew Quon, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00547742     History of Changes
Other Study ID Numbers: VAR0011, 96184, VAR0011
Study First Received: October 19, 2007
Last Updated: July 16, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on August 01, 2014